UNSPSC 51282523: Cefalexin monohydrate

This classification denotes a cephalosporin antibiotic with the molecular structure C16H17N3O4S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, OBN7UDS42Y chemically known as (6r,7r)-7-((r)-2-amino-2-phenylacetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid monohydrate, but more commonly known as cephalexin, which bears US NIH Compound Identifier 2666. European Medicines Agency schedules Cephalexin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06165MIG.

Most nations, for tariff and trade purposes, schedule cefalexin monohydrate under HS 29419000. SMILES: CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3CCCCC3)N)SC1)C(=O)O.O.

UNSPSC 51282523 Cefalexin monohydrate is a Commodity code tracking pharmaceutical products in state and local procurement. Recent opportunities show that state and local governments use this code to solicit antibiotic and emergency medical products through cooperative purchasing consortia and county health programs. The solicitations posted under this code do not consistently align with cefalexin itself; instead, the issuing bodies are purchasing a broader range of pharmaceuticals including antibiotics and emergency supplies such as naloxone and drug deactivation systems. The mix of issuing bodies includes state health departments and county health authorities, often leveraging cooperative vehicles such as MMCAP (Infuse consortium) to aggregate demand and distribute contracts to pharmaceutical suppliers and warehouse distributors.

Activity appears concentrated in Illinois and Florida based on recent postings. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through MMCAP Infuse to Chartwell Rx LLC in August 2026 for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets, totaling $2,999,999.11 over a 12-month initial term plus two optional renewal years. Seminole County, Florida released an IFB in June 2026 (due July 26, 2026, though the reference date appears inconsistent in the source) for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, including a two-year initial contract term with one-year renewal option. Both solicitations require vendors to meet standard compliance certifications, drug-free workplace status, and E-Verify participation; the Seminole County procurement included potential FEMA funding and associated federal compliance overlays.